Twist Bioscience (NASDAQ:TWST) Price Target Raised to $48.00

Twist Bioscience (NASDAQ:TWST) had its price target increased by Robert W. Baird from $46.00 to $48.00 in a report published on Tuesday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

TWST has been the subject of several other reports. Barclays decreased their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Leerink Partners raised their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Evercore ISI raised their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, JPMorgan Chase & Co. raised their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average price target of $51.78.

Twist Bioscience Stock Up 1.9 %

Shares of TWST opened at $41.89 on Tuesday. The stock has a market capitalization of $2.49 billion, a P/E ratio of -11.57 and a beta of 1.78. Twist Bioscience has a twelve month low of $23.07 and a twelve month high of $60.90. The company has a 50 day moving average of $43.93 and a 200-day moving average of $46.15.

Insider Buying and Selling at Twist Bioscience

In related news, CEO Emily M. Leproust sold 1,730 shares of the firm’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $46.94, for a total value of $81,206.20. Following the transaction, the chief executive officer now owns 495,523 shares in the company, valued at approximately $23,259,849.62. This trade represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Adam Laponis sold 856 shares of the firm’s stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $41.81, for a total value of $35,789.36. Following the completion of the transaction, the chief financial officer now owns 73,397 shares in the company, valued at $3,068,728.57. The trade was a 1.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 98,118 shares of company stock valued at $4,391,151 in the last quarter. 3.92% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its position in Twist Bioscience by 1.9% in the third quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock valued at $61,807,000 after acquiring an additional 26,145 shares during the last quarter. Barclays PLC grew its position in Twist Bioscience by 214.8% in the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock valued at $6,913,000 after acquiring an additional 104,420 shares during the last quarter. XTX Topco Ltd grew its position in Twist Bioscience by 36.7% in the third quarter. XTX Topco Ltd now owns 15,518 shares of the company’s stock valued at $701,000 after acquiring an additional 4,169 shares during the last quarter. Wellington Management Group LLP grew its position in Twist Bioscience by 188.5% in the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after acquiring an additional 521,272 shares during the last quarter. Finally, State Street Corp grew its position in Twist Bioscience by 19.9% in the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after acquiring an additional 526,028 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.